Tyra Corp (TYRA) - יחס שווי שוק לרווח נקי

Tyra Biosciences, Inc. (TYRA) has an adjusted P/E comparable to its strategy for combating tumor resistance and treating pediatric dysplasias. The -8.20 value shows the latest metric reading, helping to avoid overpaying for the asset. This chart confirms the intensity of clinical programs targeting bladder cancer. Developments are based on AI-driven design of targeted FGFR inhibitors, ensuring a scientific priority in precision oncology.
פילוחי מדדים מקיפים ואנליטיקה עבור Tyra Corp (TYRA)

Speculative expectations regarding the Phase 2 clinical trial results of the FGFR inhibitor are already priced into the shares of Tyra Biosciences, Inc. (TYRA), making the company's estimated P/E analysis a key tool for verifying market optimism. This multiple, reflecting the ratio of market capitalization to net income, allows for the timely identification of systemic risks and asset overvaluation, preventing capital from being frozen should the company fail to achieve its fundamental goals.